Dr. Li Chen leads Hua Medicine, a drug discovery company whose mission is to bring clinically differentiated medicines to patients in China and worldwide. Before Dr. Chen founded Hua Medicine, he was the Chief Scientific Officer and Head of Research at Roche R&D Center (China) Ltd. and a member of Roche's Pharma Research Leadership Team.
As a founding Director in this position, Li was responsible for development and implementation of China's drug discovery strategy, creation of the China discovery portfolio, and management of China operations including Biology, Chemistry, Pharmacology, Discovery Technology, Drug Supply and Drug Safety. He developed a "Collaborative Innovation" model through integration of over 100 scientist-based China partnerships with academic institutes, biotech, contract research organizations and clinical development organizations.
During his 18 year pharma career, Li also had several leadership positions at Roche Nutley in New Jersey, including head of combinatorial/high throughput chemistry. He is a co-inventor of two Roche drugs that reached Phase II clinical trials in Asthma and in MED. He also served as a member at Roche's Patent Coordination Committee at Nutley. Li was the President of the Sino-American Pharmaceutical Professionals Association (SAPA) in 2001, and is now a member of the SAPA Board of Directors. He has received numerous honors including the Roche Pharma Olympia Award 2005, Roche D2K Award, and SAPA President's Award. Most recently, he received IBC China Pharma's R&D Award, which recognizes outstanding individuals whose contributions changed the landscape, reputation, and ecosystem for drug R&D in China. He has also received the "Shanghai Leading Talent" Award from the Shanghai government. Li received his Ph.D in Chemistry from Iowa State University. He was formerly a lecturer in Organic Chemistry at East China Normal University, and is currently an adjunct professor of Chemical Biology at Tongji University. He has over 70 publications in numerous peer-reviewed scientific journals and in patent literature.
Dr. John Choi has extensive experience as a healthcare investor, executive and serial entrepreneur. In addition to being a co-founder and the CBO of Hua Medicine, he is a Venture Partner with Fidelity.
Previous to Hua, he co-founded Pytho Capital, a research-oriented, life-science specialized hedge fund investing in small-cap, public biotech companies. Before co-founding Pytho Capital, John was a Principal at the storied venture capital firm of Venrock Associates, the venture investing arm of the Rockefellers. During his tenure there, John focused on Venrock's biotechnology and medical device franchises, working actively with portfolio companies such as Coley Pharmaceuticals (acquired by Pfizer NYSE: PFE), Sirna Therapeutics (acquired by Merck NYSE: MRK), and Princeton Lightwave. He was also previously involved with investments in Nanogram Devices Corporation (acquired by Wilson Greatbatch NYSE: GB), Targeted Genetics Corporation (NASDAQ: TGEN) and led the investment in Skinetics Biosciences (acquired by Sirna Therapeutics NASDAQ: RNAI). Prior to Venrock, he worked at the San Francisco offices of TVM Capital, an international venture capital firm with offices in North America and Europe.
Before embarking on his extensive business and investing experience, John was in academia. He previously served as a Resident in the Departments of Internal Medicine and Genetics at Baylor College of Medicine. He also completed his doctoral thesis at Harvard Medical School conducting nuclear magnetic resonance (NMR) studies of human T-cell surface proteins CD2 and CD4. In addition to his Ph.D. in Biophysics from Harvard University, John received his M.D. from Cornell University Medical College, and his B.S. in Applied Math and Physics from Yale College.
Dr. Yi Zhang heads the clinical research & development team at Hua Medicine. Prior to joining Hua, Dr. Zhang was the Associate Medical Director of Clinical Science at Roche Product Development group, Asia Pacific region. She served as a clinical scientist for innovative drug development in the areas of cardiovascular, metabolic and renal diseases. Prior to Roche, Dr. Zhang was a Physician and an Associate Professor at Shanghai Ruijin Hospital, Shanghai Jiaotong University School of Medicine with more than 10 years' clinical experience. Dr. Zhang was also a team leader of the molecular genetics research group at the Shanghai Institute of Hypertension and a principle investigator for several projects supported by the National Natural Science Foundation of China and the Shanghai Municipal Natural Science Foundation. Dr. Zhang obtained her MD and PhD from Shanghai Jiaotong University School of Medicine, specialized in cardiology. She received training in molecular genetics, bioinformatics and epidemiology at the Chinese National Human Genome Center and at the Framingham Heart Study as a NIH/NHLBI visiting researcher. Dr. Zhang has received Shanghai Subject Chief Scientist and 60 publications in journals such as Nat Genet, Circ Cardiovasc Genet, Hum Mol Genet, 4 book chapters, and has 3 China patents.
Dr. Yong-Guo Li (Fred) serves as VP Pharmaceutical R&D at Hua Medicine (Shanghai) Limited, an innovative biotech company focused on developing novel therapeutics. His major responsibilities include overseeing Chemistry, Manufacture & Control (CMC) and Drug Supply, GxP compliance, and supervising Corporate Project Management. Prior to joining Hua Medicine, Dr. Li worked at Roche’s R&D Center (China) for nearly 8 years as Head of Analytics and Deputy Head of the CMC Department. He also served as a member of the Senior Management Team, Research Project Management Team, Metabolic Project Leadership Team, and was an acting Officer of Environmental Safety and Health (EHS). Before Roche, Dr Li worked at the global healthcare company Pharmanex as the Head of Analytics and Quality Assurance for 8 years. He was also a faculty member at China Pharmaceutical University for 5 years. He has published over 20 scientific articles in peer-reviewed journals and is an author of 4 book chapters. Fred is currently an Adjunct Professor at Shanghai University of Chinese Medicine.
Dr. Jin She is responsible for API manufacturing, Process Chemistry Research & Development, and Discovery Chemistry at Hua. Dr. She has over 11 years’ of experience in the biotechnology and pharmaceutical industry. Prior to Hua Medicine, he worked at MSD R&D Center (China) as Director of Process Chemistry, and Roche R&D Center (China) as Head of Process Research & Synthesis. Before returning back to China from the US, He worked at Inspire Pharmaceuticals Inc. as Sr. Research Scientist and team leader of Process Research. Dr. She has also been an Industrial Advisor for Engineering Master Program at East China Science & Technology University for the last 5 years. He has 8 publications in peer-reviewed journals and 6 patents. Dr. She Received his Ph.D. in organic chemistry from the University of North Carolina at Chapel Hill. He obtained his BS and MS degrees in chemistry from Beijing University.
Dr. Jin has over 16 years of experience in the biopharmaceutical industry. She was formerly Vice President of Discovery Biology at Medicilon, responsible for building and managing its Discovery Biology infrastructure. She has extensive experience in the areas of CNS disorders, inflammation, oncology, metabolic and cardiovascular diseases. Before returning to China, she was Team Leader for the Neurodegenerative Disease Focus Area at CombinatoRx, leading several programs in the CNS area, including Spinal Muscular Atrophy and Huntington Disease. Prior to that, she was a research scientist in the Pharmacology Department at Biogen, in charge of the molecular pharmacology function to support multiple programs in the CNS and cardiovascular disease areas including congestive heart failure and Parkinson Disease.
Dr. Jin received her PhD in Biochemistry and Pharmacology from the University of Virginia and completed her postdoctoral training at Harvard Medical School. She received her BS from the University of Science & Technology of China with highest honors. Dr. Jin has published more than 20 research papers and review articles in international journals such as Cell, Neuron, Nature Biotech., JCI, Molecular Pharmacology and MCB, and has served as invited speaker in many national and international conferences. She is also an inventor on several US national and world-wide international patents.
Dr. Haoliang Song is Director, Drug Safety Assessment at Hua Medicine. Now he is managing all the drug safety-related studies, cooperating with the partners from US, China and other countries. As a member of Hua Medicine QQLT, Dr. Song also attends the Quality control strategic development of Hua Medicine projects. Dr. Song has more than 16 years experience in hospital and biotechnology company. Before joining the company, Dr. Song worked at Medicilon as Director of Operations and Study Director to lead teams in the development of GLP and non-GLP preclinical studies. He received USFDA GLP regulation and study trainings including study design and study operations & management at US MPI RESEARCH. Prior to that, Dr. Song spent several years at HongKong Polytechnic University as Research associate and its institute of Modern Chinese Medicine as Head of Pharmacology department, leading teams in the development of pharmacology and toxicology techniques platform, where he completed the studies for the doctoral thesis. Dr. Song also had five years working experience in hospital, where he had more close attention on how to meet the patients needs. Dr. Song is the author of more than 10 publications and one of the inventors of 4 patents.
Gary Yu，Master of pharmaceutics, senior engineer. Now he serves as Director of Regulatory Affairs in Division of Clinical Research and Development. Prior to join Hua, Gary was in charge of two developing projects of innovative T2DM drug candidates and managed a series of tasks that preclinical evaluation, clinical development and regulatory affairs are included. One of these projects was supported by National Key Technologies R&D Program and has been accomplished in 2013. Gary has more than 10 years’ experience of Medical R&D project management and Pharmaceutical license progress. Gary has also participated as inventor in writing and registration of several domestic and PCT patents.